Silver Book Fact

A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.

Reisberg, Barry, Rachelle Doody, Albrecht Stöffler, Frederick Schmitt, Steven Ferris, and Hans Jörg Möbius. Memantine in Moderate-to-Severe Alzheimer’s Disease. New England Journal of Medicine. 2003; 348(14): 1333-41. http://content.nejm.org/cgi/content/abstract/348/14/1333?hits=20&where=fulltext&andorexactfulltext=and&searchterm=reisberg&sortspec=Score%2Bdesc%2BPUBDATE_SORTDATE%2Bdesc&excludeflag=TWEEK_element&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Memantine in Moderate-to-Severe Alzheimer’s Disease
Publication
New England Journal of Medicine
Publication Date
2003
Authors
Reisberg, Barry, Rachelle Doody, Albrecht Stöffler, Frederick Schmitt, Steven Ferris, and Hans Jörg Möbius
Volume & Issue
Volume 348, Issue 14
Pages
1333-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Medicare Costs, 5-Year Delayed Onset  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2…  
  • Current research supported by the National Institute of Neurological Disease Orders and Stroke (NINDS) at NIH is using animal models to study progression of the disease and develop new drugs…  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…